none
Conditions
Interventions
single oral ingestion about 250g of raw material ( fruit eatable part and seed )
Single oral ingestion 1250mL of food (beverages) containing food ingredients extracted and refined from raw materials.
Sponsors
R&D Institute, MORINAGA & CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Men and women aged 20 to 65 years at the time of obtaining consent (2) BMI of 18.5 kg/m^2or more but less than 30.0 kg/m^2. (3) Those who have completed two doses of the new coronavirus vaccine at least one week prior to the first test day. (4) Those who have received sufficient explanation of the test, understand the contents, and can give written consent in person.
Exclusion criteria
Exclusion criteria: (1) People who have difficulty with acidity (2) Those who are currently taking any medication. (3) Those who are scheduled to take medication or receive vaccinations between one week before the first test date and the second test date. (4) Heavy drinkers of alcohol (5) Those who are unable to go to bed and sleep as usual the day before the test day (6) Those who have been told that their blood vessels are too thin or that it is difficult to draw blood more than once (7) Those who are aware that they have severe symptoms such as irregular menstruation, menstrual cramps, or symptoms related to menopausal disorders. (8) Those who have a history or current history of serious diseases of the heart, liver, kidneys, digestive organs, etc. (9) Those who are pregnant, lactating, or intend to become pregnant during the study period. (10) Those with allergies to medicines or food (11) Those who are currently participating in a clinical trial of another drug or health food, and plan to participate in another clinical trial within 4 weeks of the end of the trial, or after consenting to participate in the trial. (12) Those who have donated component blood or 200 mL whole blood since the month prior to the start of the study. (13) Men who have donated 400 mL of whole blood for 3 months prior to the start of the study. (14)Women who have donated 400 mL of whole blood for 4 months prior to the start of the study (15) Men whose total blood collection volume exceeds 1200 mL when the planned total blood collection volume for the study is added to the blood collection volume from 12 months prior to the start of the study (16)Women whose blood volume exceeds 800 mL when the total planned blood volume for the study is added to the blood volume collected 12 months prior to the start of the study. (17) Patients who are judged to be inappropriate for participation in the study by the principal investigator or sub-investigator. Translated with www.DeepL.com/Translator (free version)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of intact components in blood plasma | — |
Countries
Japan
Contacts
Public ContactSadao Mori
R&D Institute, MORINAGA & CO., LTD. Health Science Research Center
Outcome results
None listed